Drugs / TQH3906
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06754891 | Jan 2025 → Jul 2027 expected | inflammatory bowel disease | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06230588 | Feb 2024 → Apr 2025 | psoriasis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07509892 | Jun 2026 → Nov 2027 expected | systemic lupus erythematosus | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07406035 | Apr 2026 → Aug 2027 expected | psoriatic arthritis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06542614 | Aug 2024 → Nov 2025 | psoriasis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQH3906 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07509892 ↗ |
| Action | Inhibit | “TQH3906 is a kinase inhibitor.” NCT06230588 ↗ |
| Modality | Small molecule | “TQH3906 is a small-molecule inhibitor of tyrosine kinase.” NCT07406035 ↗ |
| Route | Oral | “TQH3906 capsule for oral administration as a single or multiple dose for 7days.” NCT06230588 ↗ |
| Target | TYK2 | “Tyrosine Kinase 2 (TYK2) inhibitor” NCT07509892 ↗ |